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Exciting advances in stem cell biology, combined with
continued high morbidity and mortality in heart failure
patients, have resulted in a growing number of clinical trials
using adult cells to repair injured myocardium (1–6). To
date, cell types for clinical trials have been derived from
skeletal muscle, bone marrow/peripheral blood, and, most
recently, the heart itself. Cell therapy has a demonstrated
good safety proﬁle thus far, but results have been variable
and beneﬁts modest. In addition to the blood-forming cells,
for which it is famous, marrow also has a rich stromal-
vascular compartment. Marrow stromal cells are pericyte-like
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and demonstrate some properties of stem cells, with the
ability to give rise to fat, bone, and cartilage (7). Hence, they
are often called mesenchymal stem cells (MSCs). There is
a large pre-clinical literature on the use of MSCs for cardiac
repair showing evidence of improved cardiac function
and reduced remodeling in multiple animal models,
although their beneﬁts in humans remain uncertain. Origi-
nally hypothesized to differentiate into new cardiomyocytes,
MSCs are now known to engraft poorly, with the majority
persisting less than a week after transplantation. Thus, the
explanation for their beneﬁt has shifted from new myo-
genesis to secretion of paracrine factors. Multiple clinical
trials of MSCs for heart repair are under way, and in this
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The purpose of C-CURE was to evaluate the feasibility
and safety of delivering lineage-directed bone marrow–
derived MSCs for treatment of chronic ischemic heart
failure. Patients were on average 58 years of age, had a
left ventricular ejection fraction (EF) of 27.6%, and were
1,540 days from the inciting ischemic injury. Iliac crest bone
marrow cells were exposed to a cocktail of factors including
transforming growth factor-b, bone morphogenetic protein,
activin A, ﬁbroblast growth factor 2, cardiotrophin, and
a-thrombin. The authors previously reported that these
primed bone marrow MSCs demonstrate enhanced cardiac
differentiation. To target MSCs to the damaged region, the
endocardial surface was electromechanically mapped using
a NOGA catheter (Cordis, a Johnson & Johnson company,
Bridgewater, New Jersey), and 0.6 to 1.2 billion MSCs were
injected in multiple sites within the infarct and border zone
using a Myostar catheter (Cordis, a Johnson & Johnson
company).
Harvesting marrow locally, shipping it to a central lab for
processing, and returning the expanded cells for injection is
not a trivial undertaking, and the investigators achieved an
w70% overall success rate. The 30% of patients for whom
cells could not be obtained were dropped from the analysis
of the cell-treated cohort, and we are not provided with any
demographic details or whether they differed from the
patients for whom sufﬁcient cells were generated. No
patients experienced adverse clinical events attributable to
the cells over the 2-year follow-up, including abnormal
tissue growth and increased arrhythmias. Patients who
received cells showed evidence of improved function versus
the control arm, which received standard of care interven-
tion. Six months after treatment, the cell therapy group had
a 7% absolute improvement in EF over baseline, versus a
nonsigniﬁcant change in the control group. This improve-
ment in EF is dramatic, particularly given the duration
between the ischemic injury and cell therapy. It compares
favorably with our most potent therapies in heart failure.
Interestingly, the higher EF resulted largely from a decrease
in end-systolic volume, which differs from pharmacological
treatments in which EF improves via reverse remodeling
and reduced end-diastolic volume. Cell therapy was also
associated with an increase in the 6-min walk test, with
a 77-m improvement over the control group but no differ-
ence in VO2max. These ﬁndings suggest that treatment with
cytokine-primed MSCs is feasible and safe and provides
some evidence of enhanced cardiac performance, but only
a larger trial will resolve these discrepancies.
The quest to turn adult cells into a renewable source of
cardiomyocytes has been under way for>15 years. Previously,
Dr. Terzic’s group (9–12) reported that cytokine-stimulated
human MSCs expressed certain features of cardiomyocytes
not found in standard human MSCs, and they termed the
population cardiopoietic stem cells. The cardiac properties
included expression of cardiac transcription factors (MEF2C,
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2340NKX2.5, MESP-1) and, in some instances, expression of
contractile proteins without sarcomeric organization. When
transplanted into infarcted hearts of immunocompromised
rats, cytokine priming improved heart performance compared
with naïve human MSCs, and the authors reported MSC-
derived human cardiomyocyte formation in the rat heart.
Although encouraging, it is important to recognize that the
cardiogenic capacity of MSCs has been controversial. Various
manipulations have been attempted including treatment with
5-azacytidine, pre-treatment with growth factors, hypoxia
pre-conditioning, and genetic engineering (13), and none has
robustly yielded deﬁnitive cardiomyocytes. The salutary
paracrine effects of MSCs have been well documented (14)
and could be playing a role for the cardiac primed MSC
population as well. The question remains whether there is
a signiﬁcant contribution of force-generating cardiac muscle
directly derived from these “cardiopoietic” MSCs? This is
difﬁcult to resolve in a clinical trial, but sustained myogenesis
by any adult source has been difﬁcult to document, even in
animal models.
There has been much variability reported in the results of
cardiac cell therapy trials (3), and the National Heart, Lung,
and Blood Institute–sponsored Cardiovascular Cell Therapy
Research Network has not been able to reproduce the
beneﬁcial results reported by others. This may be due, in
part, to the small size of the studies but may also be related
to study design. In contrast to a classic clinical trial, patients
in the C-CURE cell therapy group whose cells did not reach
release criteria were excluded from analysis. This may bias
the analysis toward a positive effect. For example, we do not
know whether this 30% of patients represents a sicker or
less-responsive group. Although phase I trials focus on safety,
if efﬁcacy endpoints are reported, an intention-to-treat
analysis is probably warranted. Despite these limitations,
preliminary outcomes reported in the C-CURE trial are
encouraging and certainly merit a larger and blinded phase
II/III clinical trial with randomization after adequate cells
meeting release criteria have been generated.
Pharmacological therapies for heart failure plateaued after
the major advances with neurohumoral blockade, and
treatment of advanced heart failure has shifted increasingly
to mechanical methods. Although these advances have
improved outcomes, regenerating the injured myocardium
remains the transformative alternative and stem cell treat-
ment remains the most promising approach. The number of
clinical trials showing safety and feasibility from adult stem
cells is encouraging, but deﬁnitive evidence of efﬁcacy
remains elusive. Looking ahead, future clinical trials likelywill also study pluripotent stem cell derivatives, where new
myogenesis is more certain. The C-CURE trial, along with
other cardiac cell therapy trials, has provided a strong basis
to continue to explore the role of stem cells in the treatment
of injured myocardium.Reprint requests and correspondence: Dr. Charles E. Murry,
Department of Pathology, University of Washington, 850 Repub-
lican Street, Seattle, Washington 98109. E-mail: murry@uw.edu.REFERENCES
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